We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+4.4%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.06B
AUM Growth
+$28.4M
Cap. Flow
-$1.31B
Cap. Flow %
-42.81%
Top 10 Hldgs %
37.02%
Holding
95
New
15
Increased
19
Reduced
16
Closed
14
Avg Time Held
1.4 quarters
Top 10 Avg Time Held
1.4 quarters
Top 20 Avg Time Held
1.3 quarters

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$50.1M
2
BSX icon
Boston Scientific
BSX
+$37.5M
3
VRDN icon
Viridian Therapeutics
VRDN
+$30.9M
4
MRVI icon
Maravai LifeSciences
MRVI
+$24.4M
5
AXNX icon
Axonics, Inc. Common Stock
AXNX
+$21.7M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$90.4M
2
GKOS icon
Glaukos
GKOS
+$43.8M
3
AMGN icon
Amgen
AMGN
+$39M
4
ISRG icon
Intuitive Surgical
ISRG
+$30M
5
BLU
BELLUS Health Inc.
BLU
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 54.2%
2 Miscellaneous 45.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NBIX icon
1
Neurocrine Biosciences
NBIX
$13.7B
$88M 2.88%
933,362
+166,562
+22% +$16.3M
2023 Q1
1 quarter
PCVX icon
2
Vaxcyte
PCVX
$10.6B
$86M 2.81%
1,722,353
+402,375
+30% +$19.1M
2022 Q4
2 quarters
ALGN icon
3
Align Technology
ALGN
$10.1B
$79.2M 2.59%
224,030
+16,900
+8% +$5.38M
2022 Q4
2 quarters
GKOS icon
4
Glaukos
GKOS
$9.82B
$74.4M 2.43%
1,044,392
-762,259
-42% -$43.8M
2022 Q4
2 quarters
XENE icon
5
Xenon Pharmaceuticals
XENE
$3.26B
$70.4M 2.3%
1,828,353
-308,757
-14% -$12.3M
2022 Q4
2 quarters
NTRA icon
6
Natera
NTRA
$57.7B
$56.1M 1.83%
1,152,851
+170,610
+17% +$8.7M
2022 Q4
2 quarters
DCPH icon
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$51.3M 1.68%
3,646,419
+405,068
+12% +$5.8M
2022 Q4
2 quarters
IRTC icon
8
iRhythm Holdings
IRTC
$3.47B
$49.9M 1.63%
478,557
+24,388
+5% +$2.93M
2022 Q4
2 quarters
DICE icon
9
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$47.8M 1.56%
1,029,901
+45,101
+5% +$1.56M
2022 Q4
2 quarters
KROS icon
10
Keros Therapeutics
KROS
$219M
$46M 1.5%
+1,143,865
New +$50.1M
2023 Q2
0 quarters
NVRO icon
11
DELISTED
NEVRO CORP.
NVRO
$45.2M 1.48%
1,776,368
+143,453
+9% +$4.14M
2022 Q4
2 quarters
ISRG icon
12
Intuitive Surgical
ISRG
$147B
$42.3M 1.38%
123,820
-99,300
-45% -$30M
2022 Q4
2 quarters
MRUS icon
13
DELISTED
Merus
MRUS
$40.6M 1.33%
1,543,162
+70,078
+5% +$1.53M
2022 Q4
2 quarters
DAWN icon
14
DELISTED
Day One Biopharmaceuticals
DAWN
$40.1M 1.31%
3,361,813
+201,918
+6% +$2.64M
2022 Q4
2 quarters
BSX icon
15
Boston Scientific
BSX
$61.6B
$38.8M 1.27%
+717,050
New +$37.5M
2023 Q2
0 quarters
LEGN icon
16
Legend Biotech
LEGN
$3.8B
$38.4M 1.25%
556,301
-45,500
-8% -$2.97M
2022 Q4
2 quarters
FNA icon
17
DELISTED
Paragon 28, Inc.
FNA
$37.9M 1.24%
2,136,122
+1,037,400
+94% +$18.6M
2023 Q1
1 quarter
BIIB icon
18
Biogen
BIIB
$33.9B
$34.7M 1.14%
121,942
-98,800
-45% -$29.4M
2022 Q4
2 quarters
KIDS icon
19
OrthoPediatrics
KIDS
$570M
$33.4M 1.09%
761,208
-237,663
-24% -$11M
2022 Q4
2 quarters
OM icon
20
Outset Medical
OM
$72.4M
$31.9M 1.04%
97,358
-19,599
-17% -$5.98M
2022 Q4
2 quarters
ACRS icon
21
Aclaris Therapeutics
ACRS
$500M
$30.1M 0.98%
2,901,194
-367,900
-11% -$3.33M
2022 Q4
2 quarters
AXNX icon
22
DELISTED
Axonics, Inc. Common Stock
AXNX
$29M 0.95%
573,791
+407,087
+244% +$21.7M
2023 Q1
1 quarter
VRDN icon
23
Viridian Therapeutics
VRDN
$2.06B
$28.7M 0.94%
+1,206,300
New +$30.9M
2023 Q2
0 quarters
KRYS icon
24
Krystal Biotech
KRYS
$9.57B
$28.3M 0.93%
241,399
-106,637
-31% -$10.9M
2022 Q4
2 quarters
IMCR icon
25
Immunocore
IMCR
$1.45B
$28.1M 0.92%
468,027
+41,917
+10% +$2.39M
2023 Q1
1 quarter
1
2 3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q2 2023 Portfolio in Review

As of Q2 2023, Braidwell held 95 positions worth $3.06B, up 0.94% from $3.03B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $1.31B in Q2 2023, closing 14 positions and reducing 16 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $90.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 54% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Keros Therapeutics worth $46M.

  • Braidwell's largest Q2 2023 buy was Keros Therapeutics: 1,143,865 shares worth $46M.
  • Braidwell added most to Axonics, Inc. Common Stock in Q2 2023, an estimated $21.7M increase.
  • Braidwell's biggest Q2 2023 reduction was Glaukos, cutting an estimated $43.8M.
  • Braidwell fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $90.4M.
  • Braidwell's ten largest holdings make up 37% of its $3.06B portfolio in Q2 2023.
  • Braidwell opened 15 new positions and closed 14 in Q2 2023.
  • Braidwell's portfolio value rose 0.94% quarter-over-quarter to $3.06B.

Based on Braidwell's 13F filing for Q2 2023, filed 14 Aug 2023.